Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDok Hyun YoonHCHyungwoo ChoJCJason Yongsheng Chan

Discussion

Loading...

Member takes

Overview

Prospective registry shows 2-year progression-free survival of 67.5% in mantel cell lymphoma patients, indicating prevalent use of chemotherapy regimens like ibrutinib.

Key Points

  • 2-year progression-free survival rate was 67.5%, demonstrating significant outcomes for MCL treatments.
  • Majority received systemic chemotherapy, with ibrutinib used as a key 2nd line treatment for relapse.
  • Clinical data from 132 MCL patients across multiple hospitals revealed treatment patterns and outcomes.
  • Outcomes did not vary significantly with upfront ASCT or rituximab maintenance treatment.

Cite This Study

Yoon et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da50https://doi.org/10.1182/blood-2025-2778
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study2025
  2. 2Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States2025
  3. 3Real-world treatment and outcomes of Mantle Cell Lymphoma in Latin America: A multinational cohort analysis2025
  4. 4Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States2025
  5. 5Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study2025